Developmental and therapeutic implications of molecular profiles of ER-positive and ER-negative breast cancers.

被引：0
|
作者：
Perou, CM [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S3 / S3
页数：1
相关论文
共 50 条
  • [21] Serum proteomic profiling distinguishes estrogen receptor (ER) positive and ER negative breast cancers.
    Sun, M
    Sun, M
    Lyons-Weiler, J
    Lokshin, AE
    Modugno, F
    Marks, J
    Bigbee, WL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 23S - 23S
  • [22] Therapeutic strategy for ERα mutation driven-endocrine resistance in ER-positive breast cancers
    Kim, Jin-Ah
    Fuqua, Suzanne A. W.
    CANCER RESEARCH, 2018, 78 (04)
  • [23] ERβ mRNA expression in ERα-negative and triple-negative breast cancers.
    Choi, Young
    Kim, Hadong
    Kim, Tae-Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Neoadjuvant therapy for ER-positive breast cancers
    Colleoni, M.
    Montagna, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 243 - 248
  • [25] Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers
    Itoh, Mitsuya
    Iwamoto, Takayuki
    Matsuoka, Junji
    Nogami, Tomohiro
    Motoki, Takayuki
    Shien, Tadahiko
    Taira, Naruto
    Niikura, Naoki
    Hayashi, Naoki
    Ohtani, Shoichiro
    Higaki, Kenji
    Fujiwara, Toshiyoshi
    Doihara, Hiroyoshi
    Symmans, W. Fraser
    Pusztai, Lajos
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (02) : 403 - 409
  • [26] Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers
    Mitsuya Itoh
    Takayuki Iwamoto
    Junji Matsuoka
    Tomohiro Nogami
    Takayuki Motoki
    Tadahiko Shien
    Naruto Taira
    Naoki Niikura
    Naoki Hayashi
    Shoichiro Ohtani
    Kenji Higaki
    Toshiyoshi Fujiwara
    Hiroyoshi Doihara
    W. Fraser Symmans
    Lajos Pusztai
    Breast Cancer Research and Treatment, 2014, 143 : 403 - 409
  • [27] Significance and Therapeutic Potential of PELP1 in ER-Negative Breast Cancers
    Roy, S. S.
    Chakravarty, D.
    De, K.
    Tekmal, R. R.
    Sun, L. Z.
    Vadlamudi, R.
    CANCER RESEARCH, 2010, 70
  • [28] Evaluation of the prevention by pioglitazone/metformin of ER-positive and ER-negative mammary cancers occurring in rodents on a high-fat diet
    Dunn, Barbara K.
    Suen, Chen
    Grubbs, Clinton
    CANCER RESEARCH, 2018, 78 (13)
  • [29] Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer
    Chimge, Nyam-Osor
    Ahmed-Alnassar, Sara
    Frenkel, Baruch
    CELL CYCLE, 2017, 16 (04) : 312 - 318
  • [30] Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
    Wapnir, Irene L.
    Price, Karen N.
    Anderson, Stewart J.
    Robidoux, Andre
    Martin, Miguel
    Nortier, Johan W. R.
    Paterson, Alexander H. G.
    Rimawi, Mothaffar F.
    Lang, Istvan
    Manuel Baena-Canada, Jose
    Thurlimann, Beat
    Mamounas, Eleftherios P.
    Geyer, Charles E., Jr.
    Gelber, Shari
    Coates, Alan S.
    Gelber, Richard D.
    Rastogi, Priya
    Regan, Meredith M.
    Wolmark, Norman
    Aebi, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (11) : 1073 - +
12345